PubMed HealthSearch

PubMed · 8307657

A rule-based postoperative pain controller: simulation results.

Abstract

We describe a system for controlling postoperative pain, a phenomenon that is difficult to treat by conventional control methods due to interpatient variability, interferences, non-linearity and the lack of a plausible, well-defined mathematical model. The system consists of two phases. In Phase 1 a closed-loop fuzzy controller implementing a suitable control strategy brings the patient to a zero-pain state. In Phase 2, an open-loop computer-assisted continuous infusion controller maintains a constant concentration of the analgesic (alfentanil) in plasma, subject to an upper safety limit on infusion rate; the set-point of this controller is periodically revised (either maintained or reduced) on the basis of feedback on the duration of zero pain (set-point reduction is necessary because the open-loop system has no means of knowing whether analgesic is accumulating in the patient). Pain is quantified by the patient on a numerical scale of 1 to 10 at 1.5-min intervals during Phase 1 and 9-min intervals during Phase 2. In simulation trials in which a fixed approximate model was used for the effect of sedation on pain while the pharmacokinetics of alfentanil were varied from one simulated patient to another, zero pain was achieved in under 15 min with minimal overshoot in plasma drug concentration and was maintained, with only minor deviation, by means of low drug concentrations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Carollo, A Tobar, C Hernandez. 1993. A rule-based postoperative pain controller: simulation results.. https://doi.org/10.1016/0020-7101(93)90040-d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effects of neonatal naltrindole treatment on antinociceptive and behavioral responses to mu and kappa agonists in rats.

The effects of a daily injection of the delta selective opioid antagonist naltrindole (1 mg/kg), from birth to postnatal day 19, on antinociceptive and behavioral responses to the mu selective agonist alfentanil (65 microg/kg) and the kappa selective agonist CI-977 (50 microg/kg) in 20-day-old male rats were investigated. Antinociception was assessed using the tail immersion test and behavioral testing was performed by employing an open field. The functional blockade of the delta receptor by naltrindole blocked the antinociceptive response to alfentanil but did not affect the antinociception induced by CI-977. The effects of alfentanil (increased exploration) and CI-977 (a marked hypoactivity) in the open field were not modified by neonatal naltrindole treatment. The results suggest a functional interaction between delta and mu receptors in the postnatal period but not between delta and kappa receptors. The data also suggest differences in the delta and mu receptors interacting in the modulation of antinociception and those involved in behavioral responses in the open field.

Alfentanil

Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output.

BACKGROUND: Cardiac output (CO) is likely to influence the pharmacokinetics of anesthetic drugs and should be accounted for in pharmacokinetic models. The influence of CO on the pharmacokinetic parameters of alfentanil in pigs was evaluated using compartmental and recirculatory models. METHODS: Twenty-four premedicated pigs were evaluated during halothane (0.6-2%) anesthesia. They were assigned randomly to one of three groups. One group served as control. In the other groups, the baseline CO was decreased or increased by 40% by pharmacologic intervention (propranolol or dobutamine). Boluses of alfentanil (2 mg) and indocyanine green (25 mg) were injected into the right atrium. Blood samples were taken for 150 min from the right atrium and aortic root. Arterial concentration-time curves of indocyanine green and alfentanil were analyzed using compartmental models (two-stage and mixed-effects approach) and a recirculatory model, which can describe lung uptake and early distribution. RESULTS: The CO of individual pigs varied from 1.33 to 6.44 l/min. Three-compartmental modeling showed that CO is a determinant of the central compartment volume (V1, r2 = 0.54), fast peripheral compartment volume (V2, r2 = 0.29), steady state distribution volume (Vss, r2 = 0.29), fast distribution clearance (Cl12, r2 = 0.39), and elimination clearance (Cl10, r2 = 0.51). Recirculatory modeling showed that CO is a determinant of total distribution volume (r2 = 0.48), elimination clearance (r2 = 0.54), and some distribution clearances. The pulmonary distribution volume was independent of CO. CONCLUSIONS: Cardiac output markedly influences the pharmacokinetics of alfentanil in pigs. Therefore, accounting for CO enhances the predictive value of pharmacokinetic models of alfentanil.

Alfentanil